Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (NYSE: TEVA) reported that Moody’s Ratings upgraded Teva’s corporate credit rating to Baa3 from Ba1, an investment-grade level, with a stable outlook. Moody’s indicates the move reflects Teva’s growth strategy, innovative products, expanded pipeline and ongoing debt reduction supported by earnings growth.
Moody’s also highlighted Teva’s revenue diversity, improving operating margins, solid free cash flow and ample cash, and expects further debt reduction over the next 12–18 months. The action follows a Fitch upgrade in May 2026 and supports Teva’s eligibility for leading fixed-income indices.
Medincell (Euronext: MEDCL) and partner Teva (NYSE/TASE: TEVA) report that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270–$290 million, from $250–$280 million.
According to Teva, based on IQVIA data, UZEDY® remains the fastest-growing long-acting injectable schizophrenia treatment in the U.S., with U.S. prescriptions (in months of therapy) up 63% year-on-year and over 800 new prescribers added per month. Medincell receives mid- to high-single-digit royalties on UZEDY® net sales and may earn up to $105 million in commercial milestones upon meeting annual sales thresholds. UZEDY® is approved in the U.S. for schizophrenia and Bipolar I Disorder, and regulatory milestones for Teva’s once-monthly olanzapine LAI are expected in Q4 2026 in the U.S., with a European Marketing Authorization Application accepted in Q2 2026.
Teva (NYSE: TEVA), partner of Medincell, reported record U.S. Q2 2026 net sales of $77 million for long-acting injectable schizophrenia treatment UZEDY, up 43% year-on-year. Teva raised its 2026 UZEDY revenue outlook to $270–$290 million, from $250–$280 million.
According to Medincell, UZEDY remains the fastest-growing long-acting injectable schizophrenia therapy in the U.S., with prescriptions (months of therapy) up 63% year-on-year and more than 800 new prescribers added monthly. Medincell receives mid- to high-single-digit royalties on UZEDY net sales and may earn up to $105 million in commercial milestones, conditional on annual sales thresholds.
UZEDY, a subcutaneous risperidone LAI, is approved in the U.S. for schizophrenia (one- and two-month dosing) and Bipolar I Disorder (one-month dosing). Teva’s once-monthly olanzapine LAI has a U.S. FDA action anticipated in Q4 2026, with FDA and EMA applications already accepted.
Teva (NYSE: TEVA) reported Q2 2026 revenues of $4.1 billion, down 1% year-over-year in U.S. dollars, as weaker generics, particularly U.S. lenalidomide, offset strong growth in key innovative brands. AUSTEDO, AJOVY and UZEDY grew 43% in local currency to over $1 billion of revenue, and Teva raised their 2026 combined outlook to about $3.7 billion, implying ~17% growth at the midpoint.
The company recorded a GAAP net loss of $576 million (loss per share $0.49) driven largely by $726 million of Emalex/ecopipam-related expenses, while non-GAAP diluted EPS was $0.02. Adjusted EBITDA fell 62% to $474 million, but free cash flow reached $622 million. Teva acquired Emalex and submitted an NDA for ecopipam in Tourette syndrome, advanced late-stage assets including olanzapine LAI and duvakitug, and continued biosimilar launches and collaborations. 2026 guidance was reiterated for revenue ($16.5–$16.85 billion), non-GAAP operating income ($3.8–$4.0 billion), adjusted EBITDA ($4.23–$4.53 billion) and free cash flow ($2.0–$2.4 billion). Teva will replace its ADS program with a direct NYSE listing of ordinary shares in September 2026.
Teva (NYSE:TEVA) and Polpharma Biologics signed a global licensing deal for a proposed biosimilar to Ocrevus (ocrelizumab) for multiple sclerosis, covering intravenous and subcutaneous forms.
Polpharma Biologics will develop and manufacture; Teva will handle regulatory submissions and commercialization in key global markets, supporting Teva’s Pivot to Growth biosimilars strategy and broader access to biologic medicines.
Teva (NYSE:TEVA) plans to advance TEV-’408, its investigational anti-IL-15 antibody designed for quarterly subcutaneous dosing, into a Phase 2b vitiligo study in Q4 2026. The move follows an open-label Phase 1b trial in non-segmental vitiligo showing skin repigmentation and no observed safety signals to date.
At week 24, evaluable patients reported facial and total body improvements, including 42% achieving F-VASI50, 21% F-VASI75, and 7% T-VASI50. Nearly 75% reported facial vitiligo improvement, with half describing themselves as “much” or “very much” improved.
Teva (NYSE:TEVA) announced its Q2 2026 Aide Memoire is now available on the investors page of its website. The document compiles previously disclosed public information to help investors prepare for second quarter 2026 results, expected on July 29, 2026, at 7:00 a.m. ET, followed by an earnings conference call at 8:00 a.m. ET.
Teva (NYSE:TEVA) submitted a New Drug Application to the FDA for ecopipam, a first-in-class investigational therapy for pediatric Tourette syndrome. The drug is a selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.
The NDA is backed by Phase 3 data in JAMA Neurology showing ecopipam significantly delayed time to relapse versus placebo (primary endpoint p = 0.008) and was generally well tolerated, with common adverse events including somnolence, insomnia, anxiety, fatigue and headache.
Teva (NYSE:TEVA) will publish its second quarter 2026 financial results on July 29, 2026 at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. Investors must register in advance for dial-in details. A webcast replay will be available within 24 hours.
Teva (NYSE:TEVA) closed its acquisition of Emalex Biosciences, adding ecopipam, a late-stage investigational treatment for pediatric Tourette syndrome, to its neuroscience pipeline. Teva paid $700 million upfront, with up to $200 million in potential commercial milestones, plus net sales-based royalties.
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. Phase 3 data were published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026, supporting Teva’s Pivot to Growth strategy.